趋化因子及趋化因子受体在骨肉瘤中的研究进展  

Research progress of chemokines and chemokine receptors in osteosarcoma

作　　者：陈泉池 华莹奇[1] 左冬青[1] 曾辉[1] 蔡郑东[1] 

机构地区：[1]同济大学附属第十人民医院骨科,上海200072

出　　处：《中国骨与关节杂志》2014年第7期544-547,共4页Chinese Journal of Bone and Joint

摘　　要：骨肉瘤，又称成骨肉瘤，是最常见的恶性成骨性肿瘤之一，占恶性骨肿瘤总数的20%～45%，多数起源于骨间叶细胞。发病年龄多在15～25岁之间，男性多于女性。好发部位为长骨干骺端，其中以股骨远端和胫骨近端较多见，其次是肱骨和腓骨近端，随血液运行转移率高且早，发展迅速。骨肉瘤侵袭性强，约20%的患者发生转移，肺转移最为常见[1]。随着新辅助化疗、保肢手术等的开展，骨肉瘤患者5年生存率提高到60%～70%[2]。但由于化疗耐药性、转移率高等问题的存在，患者仍面临着复发及肺转移的困扰。基因治疗、免疫治疗和分子靶向治疗等生物治疗技术的发展也为骨肉瘤的治疗开辟了新的道路，为骨肉瘤患者带来新的希望[3]。Osteosarcoma is the most common primary malignant tumors in childhood and adolescence, and easily develops metastasis, especially in the lung. Patients with primary and metastatic tumors have a poor prognosis. Therefore, it is necessary to do some research on the genes associated with the malignancy of osteosarcoma and to ifnd the targeted genes in the treatment of osteosarcoma. In recent years, more and more research on chemokines and chemokine receptors has been performed in oncology, which has gained increasing attention of investigators. The chemokines and chemokine receptors have been found to be important regulators in the occurrence, development and metastasis of osteosarcoma. They are thought to be active participants in the biology of osteosarcoma. Firstly, this study aims to introduce the structure, classiifcation and biological function of chemokines and chemokine receptors. Secondly, the research progress of chemokines and chemokine receptors in oncology will be presented in 4 aspects, including the effects of chemokines and chemokine receptors on tumor growth and tumor cell survival and senescence, their effects on tumor angiogenesis, on tumor metastasis and on tumor microenvironment. At last, the research progress of chemokines and chemokine receptors in osteosarcoma will be introduced, aimed at the study of their specific targeted drugs. The current problems and future prospects of chemokines and chemokine receptors in osteosarcoma will also be clariifed.

关 键 词：成骨肉瘤 趋化因子受体 恶性骨肿瘤 生物治疗技术 分子靶向治疗 胫骨近端 基因治疗 成骨性肿瘤 

分 类 号：R738.1[医药卫生—肿瘤]